Key result
miR-9-5p agomir improves LVEF and attenuates cardiomyocyte pyroptosis by targeting ELAVL1 in diabetic mice.
Why the study?
Recurrent hypoglycemia during intensive glycemic control in diabetes is an independent risk factor for cardiovascular events and all-cause mortality, but the molecular mechanisms and post-transcriptional regulatory networks underlying its myocardial damage remain poorly understood.
Does miR-9-5p targeting of ELAVL1 inhibit NLRP3 inflammasome activation and attenuate myocardial injury in preclinical models of diabetic recurrent hypoglycemia?
Does miR-9-5p targeting of ELAVL1 inhibit NLRP3 inflammasome activation and attenuate myocardial injury in preclinical models of diabetic recurrent hypoglycemia?
This preclinical study identifies the miR-9-5p/ELAVL1/NLRP3 axis as a key regulator of cardiomyocyte pyroptosis and a potential therapeutic target for attenuating myocardial injury induced by recurrent hypoglycemia in diabetes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for miR-9-5p modulation in diabetic hypoglycemia injury; leaves open human translation pending prospective trials.
OBJECTIVE: Recurrent hypoglycemia during intensive glycemic control in diabetes is an independent risk factor for cardiovascular events and all-cause mortality, yet the molecular mechanisms underlying its myocardial damage remain poorly understood. This study aimed to investigate the role of post-transcriptional regulatory networks in diabetic recurrent hypoglycemic myocardial injury. METHODS: Type 2 diabetic mouse models were established using a high-fat diet combined with streptozotocin (STZ) injection, and recurrent hypoglycemia was induced by repeated insulin administration. Integrated mRNA-seq and small RNA-seq were performed to screen differentially expressed genes and microRNAs (miRNAs). Key upstream regulators of the NLR family pyrin domain containing 3 (NLRP3) inflammasome were identified via Pearson correlation analysis combined with predictions from the StarBase, TargetScan, and miRDB databases. Direct binding between miRNA and target gene was verified by dual-luciferase reporter assays. Gain- and loss-of-function experiments were conducted in a diabetic hypoglycemic HL-1 cardiomyocyte model by transfection with miR-9-5p mimics/inhibitor and ELAV-like protein 1 (ELAVL1)-targeting short hairpin RNA (sh-ELAVL1). In vivo intervention and rescue experiments were performed via tail vein injection of miR-9-5p agomir/antagomir and sh-ELAVL1 lentivirus. Myocardial structure and function were evaluated using echocardiography, hematoxylin-eosin (HE) staining, immunofluorescence, and Western blot. RESULTS: Mice with diabetic recurrent hypoglycemia exhibited significant weight loss (p < 0.001) and impaired cardiac function. Transcriptome analysis identified 42 differentially expressed genes between the diabetic (DM) and diabetic hypoglycemic (HDM) groups, with specific enrichment of the NOD-like receptor signaling pathway. Protein levels of NLRP3, cleaved caspase-1 (p20), and the N-terminal fragment of gasdermin D (GSDMD-N, p30) in the myocardium were further significantly upregulated in the HDM group compared with the DM group (p < 0.001). Correlation analysis combined with StarBase database screening identified ELAVL1 as the key upstream RNA-binding protein regulating NLRP3 (r = 0.82, p < 0.001). Small RNA sequencing revealed 16 significantly downregulated miRNAs in the HDM group versus the DM group. Intersection with TargetScan and miRDB predictions of ELAVL1-targeting miRNAs identified miR-9-5p as the sole candidate, which was significantly downregulated in the HDM group (p < 0.001). Dual-luciferase reporter assays confirmed direct binding of miR-9-5p to the 3' untranslated region (3'UTR) of ELAVL1 (p < 0.001). In vitro, transfection with miR-9-5p mimics significantly reduced the protein levels of ELAVL1, NLRP3, and cleaved caspase-1 (p < 0.001), increased cell viability, and decreased lactate dehydrogenase (LDH) release (p < 0.001). Conversely, miR-9-5p inhibitor promoted these pathological changes, which were fully reversed by sh-ELAVL1 (p < 0.001). In vivo, miR-9-5p agomir significantly improved left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) (both p < 0.01), inhibited co-localization of NLRP3 with apoptosis-associated speck-like protein containing a CARD (ASC), and downregulated the protein levels of GSDMD-N, interleukin-1β (IL-1β), and interleukin-18 (IL-18) (p < 0.001). miR-9-5p antagomir exacerbated these injuries, which were effectively reversed by co-administration of sh-ELAVL1 (p < 0.001). CONCLUSION: Our findings demonstrate that miR-9-5p directly targets ELAVL1 to inhibit NLRP3 inflammasome activation and cardiomyocyte pyroptosis, thereby attenuating myocardial injury and improving cardiac function in diabetic recurrent hypoglycemia. The miR-9-5p/ELAVL1/NLRP3 axis may represent a promising therapeutic target for diabetic hypoglycemic myocardial injury, although clinical validation of this axis in patients with diabetes remains to be performed.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied Diabetic recurrent hypoglycemic myocardial injury. miR-9-5p agomir/mimics, miR-9-5p antagomir/inhibitor, and sh-ELAVL1 lentivirus vs. Diabetic (DM) and diabetic hypoglycemic (HDM) control groups was evaluated on Left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and NLRP3 inflammasome/pyroptosis markers (ELAVL1, NLRP3, cleaved caspase-1, GSDMD-N, IL-1β, IL-18) (p=<0.001). MiR-9-5p agomir improved LVEF and LVFS and reduced GSDMD-N, IL-1β, and IL-18 by targeting ELAVL1 in diabetic hypoglycemic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: